Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 26th, 2026

LECO_Weekly-Healthcare-News_10-26-2026Download

Healthcare News and Deals

  1. EQT Private Equity has agreed to acquire QIAGEN N.V. (NYSE: QGEN) in a recommended all-cash voluntary public takeover offer valuing the molecular testing company at approximately $12.1 billion enterprise value. EQT XI, through Crown NL Bidco, is offering €46.50 per share in cash — a 40.3% premium to the unaffected XETRA close on July 8. Including about $1.1 billion of net debt, the deal values QIAGEN at roughly $12.1 billion. The Dutch tools and diagnostics company has been the subject of takeover talk for years. Both boards are recommending the offer after a strategic review. Affiliates of the Abu Dhabi Investment Authority and Canada Pension Plan Investment Board are co-investing. QIAGEN will keep its name and brand. (Link)
  2. HealthSpan Partners to Acquire Surgery Partners, Establishing a Leading Outpatient Surgical Care Platform HealthSpan Partners has agreed to buy Surgery Partners (NASDAQ: SGRY), the Bain Capital-backed operator of ambulatory surgery centers and surgical hospitals. Reports put the value at about $6 billion, including roughly $3.5 billion of debt, with Bain keeping its nearly 40% stake. Surgery Partners runs more than 170 surgical facilities across 30 states. HealthSpan is an affiliate of Bon Secours Mercy Health and is picking up a large outpatient surgical footprint. (Link)
  3. AEA Investors-Backed American Oncology Network Agrees to a $2.4 Billion Sale to Cencora, Adding 350+ Community Oncology Providers to Cencora’s Physician MSO Platform. Cencora (NYSE: COR) signed a definitive agreement on October 20 to buy the roughly 96% of Fort Myers-based American Oncology Network (OTCQX: AONC) it does not already own. The deal values AON at $2.4 billion enterprise value — $2.3 billion at closing plus up to $100 million in contingent value rights. Some AON holders can roll up to 25% of their equity; if they do, Cencora expects to write a check of about $1.7 billion for 75% ownership. AON brings more than 350 providers across 21 states and adds 12 new states to Cencora’s MSO footprint. Clinical decisions stay with AON physicians. It is Cencora’s fourth physician-platform deal since January 2025, after Retina Consultants of America, OneOncology and the EyeSouth retina business. (Link)
  4. Kohlberg Is Buying Alcanza Clinical Research from Martis Capital for Approximately $800–850 Million Axios Pro reported that Kohlberg is buying Alcanza Clinical Research from Martis Capital for between $800 million and $850 million. Alcanza is a clinical research site network founded in 2021 that focuses on inclusive trial access and runs more than 25 sites across the U.S. and Puerto Rico. It does Phase I–IV studies for pharma sponsors and CROs. (Link)
  5. Blackstone- and TPG-Backed Hologic Signs a Definitive Agreement to Acquire Reveal Genomics, Maker of the HER2DX Breast Cancer Test Hologic, now owned by Blackstone and TPG after a take-private of up to about $18.3 billion, has agreed to buy Barcelona-based Reveal Genomics. Reveal makes the HER2DX genomic test, which helps guide therapy for HER2-positive breast cancer. The test sits alongside Hologic’s Breast Cancer Index assay and adds another treatment-selection tool. It is the first clear sign that the new owners plan to use Hologic as a buy-and-build platform in women’s-health diagnostics. (Link)
  6. Apogem Capital Leads a Minority Investment in Revelstoke-Backed Family Care Center, Returning Capital to LPs While Revelstoke Stays In Family Care Center, the outpatient mental health platform backed by Revelstoke Capital Partners, closed a minority equity sale led by Apogem Capital. Revelstoke is staying in. Since Revelstoke partnered with founder Dr. Chuck Weber in December 2020, the company has grown entirely by opening new clinics — from four locations in one state to more than 50 across five states. It now has more than 800 providers and expects nearly 1 million treatment sessions in 2026, across therapy, psychiatry, TMS and intensive outpatient programs. Revelstoke described the deal as a way to return capital to its LPs without selling the whole company. Jefferies advised Family Care Center. (Link)
  7. EQT-Backed Sagility Agrees to Acquire Tennessee’s Chirok Health for Up to $32.35 Million, Adding Clinical Documentation Integrity and Coding Capability Sagility (US) Holdings, a subsidiary of the EQT-backed healthcare BPO Sagility, signed a definitive agreement on October 21 to buy Chirok Health, a Tennessee firm that does revenue cycle management, clinical documentation integrity and medical coding. The price is $20 million at closing plus up to $12.35 million in earnout. Chirok did about $9 million of revenue in 2025. The deal adds provider-side capability for Sagility. (Link)
  8. Altaris-Backed Tegria Acquires CloudWave, Its First Add-On Since the Providence Carve-Out, to Build a Healthcare Cybersecurity and Hosting Platform Tegria, the healthcare consulting, managed services and technology company that Altaris carved out of Providence in January 2026, bought CloudWave. CloudWave does cloud hosting, managed IT and cybersecurity (LECO sold BlueOrange to Cloudwave in 2025) only for healthcare clients, and it runs a dedicated 24/7 security operations center. CloudWave CEO Erik Littlejohn becomes president of Tegria’s Enterprise Technical Solutions. It is Tegria’s first add-on since the carve-out. (Link)
  9. Renovus Capital Partners Strikes a Deal for Chicagoland Orthopedic Home Health Provider Aspire Home Health Care Renovus Capital Partners, the Philadelphia-area lower-middle-market firm that already owns Louisiana home health and hospice platform Superior Health Holdings, has agreed to buy Aspire Home Health Care. Aspire was founded in 2013 and is based in Morton Grove, Illinois. It provides skilled nursing and therapy at home for patients recovering from orthopedic procedures, surgeries and complex conditions. The deal gives Renovus a post-surgical home health business in the Chicago market. (Link)
  10. Kohlberg-Backed Trinity Life Sciences Acquires Verix to Add AI-Driven Commercial Execution Tools for Pharma Trinity, the life sciences commercialization advisory and analytics firm that Kohlberg & Company has owned since 2021, bought Verix. Verix’s Tovana platform uses AI to give pharmacommercial teams next-best-action recommendations, patient finding and HCP targeting, and it is used by large pharma companies. The deal moves Trinity from strategy and insights into software that field teams actually use day to day. (Link)
  11. New Harbor Capital’s LGM Pharma Acquires New Jersey Contract Lab Sannova Analytical LGM Pharma, the API sourcing and CDMO platform that New Harbor Capital has majority-owned since 2017, bought Sannova Analytical. Sannova is a Somerset, New Jersey contract lab that does bioanalytical and CMC testing for pharma and biotech companies. It had been backed by SFW Capital Partners since 2022. The deal adds an East Coast testing operation to LGM’s development and manufacturing services. (Link)
  12. Blue Sea Capital-Backed One Physics Adds Two West Coast Medical Physics Firms, Expanding into the Pacific Northwest and Northern California One Physics, the largest outsourced medical physics company in North America, is buying two firms that do diagnostic medical physics and radiation safety work in the Pacific Northwest and Northern California. Blue Sea Capital has backed One Physics since 2019 and moved it into a single-asset continuation vehicle earlier this year. The company has already done 22 acquisitions and serves more than 7,000 client sites in 45+ states with over 210 physicists. (Link)
  13. HCAP Partners- and Salt Creek-Backed Real Diagnostics Adds Saliva-Based Oral Health Testing Firm SimplyTest Real Diagnostics (RealDx), the Maryland-based high-complexity molecular lab that Salt Creek Capital and HCAP Partners bought in September 2025, acquired SimplyTest. SimplyTest makes saliva-based tests, including its PERIO test, that identify bacteria linked to gum disease, and it sells to dentists and functional medicine practices. The add-on gives RealDx, which serves physician offices and clinics in 17 states, a cash-pay dental product line next to its reimbursed UTI, STI and respiratory testing. (Link)
  14. Thompson Street Capital-Backed Savillex Completes Carve-Out of Entegris’ Life Sciences Fluid Management Business Savillex, the Eden Prairie, Minnesota high-purity fluoropolymer and single-use bioprocessing company backed by Thompson Street Capital Partners, completed its acquisition of Entegris’ (Nasdaq: ENTG) life sciences fluid management business. The business includes Aramus and PE bioprocess bags, single-use assemblies and components. The carve-out deepens Savillex’s position with biopharma and cell and gene therapy manufacturers, and lets Entegris focus on semiconductor materials. It follows Savillex’s 2024 acquisition of Optimum Processing. Sidley advised Savillex. (Link)
  15. Sopris Capital Merges the Blackford Analysis Imaging-AI Platform, Carved Out of Bayer, into Portfolio Company Azra AI Azra AI said on October 20 that it had completed the acquisition of Blackford Analysis from Sopris Capital. Sopris had carved Blackford out of Bayer earlier in the month. Blackford’s vendor-neutral orchestration platform gives radiology departments access to more than 130 imaging-AI applications from 45+ vendors. Azra identifies patients with cancer and other complex conditions and coordinates their follow-up care. Putting the two together connects the imaging finding to the care pathway that follows it. (Link)
  16. Pacific Lake Partners-Backed Vitana Pediatric & Orthodontic Partners Acquires Louisiana’s Hollis Orthodontics, Its Fifth Deal of 2026 Vitana Pediatric & Orthodontic Partners, a dentist-led partnership organization backed by Pacific Lake Partners that focuses only on pediatric dental and orthodontic practices, bought Hollis Orthodontics in Prairieville, Louisiana, outside Baton Rouge. The practice is led by Dr. Bryan Hollis. Vitana now supports practices in Florida, Alabama, Louisiana, Pennsylvania and New Jersey. This is its fifth deal of 2026. (Link)
  17. DuneGlass Capital-Launched Aviva Aesthetics Enters Florida Through a Partnership with Allenby Cosmetic Dermatology Aviva Aesthetics, the founder-led medical aesthetics network that DuneGlass Capital launched, partnered with Allenby Cosmetic Dermatology, the practice of cosmetic dermatologist Dr. Janet Allenby. It is Aviva’s first Florida location, about seven weeks after the Perfect Skin Center partnership took the platform to 20 sites. Aviva markets its “Entrepreneur Equity” model to founders who have turned down traditional private equity MSO structures: founders keep decision-making authority and financial upside. (Link)
  18. Redesign Health and Sheba Medical Center’s ARC Global Merge in an Approximately $2 Billion Combination to Build an End-to-End Health System Innovation Platform Redesign Health, the venture and applied technology firm that has launched more than 60 healthcare companies, is merging with ARC Global, the innovation arm of Israel’s Sheba Medical Center. The combined company is valued at about $2 billion, according to a source familiar with the deal. The parties have also agreed to buy AVIA, the health-system digital technology advisory firm. Brett Shaheen will be CEO; Stephen Klasko, M.D., will chair the board; and ARC founder Eyal Zimlichman, M.D., will become vice chair. The idea is to put engineering, AI and capital inside health systems so clinician-originated ideas can become products and companies that scale across a network of more than 100 systems. (Link)
  19. Horizon Mutual Holdings, parent of Horizon Blue Cross Blue Shield of New Jersey, has entered an agreement to acquire Summit Health New Jersey, including its New Jersey CityMD urgent care centers, in a transaction reported at more than $1 billion. Horizon confirmed the agreement, which is subject to regulatory review and could close by year-end. Summit Health is one of New Jersey’s largest multispecialty physician networks; the New Jersey portion includes primary, specialty and 39 CityMD urgent care sites. It is Horizon’s largest deal since its 2022 conversion to a nonprofit mutual holding company. Horizon said the acquisition is meant to preserve access, improve quality and affordability for members, and support continued independence of Summit’s physicians. (Link)
  20. Alcon Acquires Rhode Island’s Neurotech Pharmaceuticals for $550 Million Plus Milestones, Picking Up ENCELTO, the Only FDA-Approved MacTel Type 2 Therapy Alcon completed the acquisition of Neurotech Pharmaceuticals on October 20 for $550 million upfront, plus possible contingent payments tied to commercial milestones. The deal brings in ENCELTO (revakinagene taroretcel-lwey), an encapsulated cell therapy implant approved in March 2025 and the only FDA-approved treatment for macular telangiectasia type 2. Neurotech estimates there are about 25,000 MacTel patients in the U.S., with 2,000 to 3,000 new diagnoses each year. Alcon expects the deal to modestly add to sales growth and slightly reduce core EPS in 2027, then add to EPS after that. (Link)
  21. Labcorp Agrees to Buy Myriad Genetics’ Prenatal Health Testing Business for $210 Million in Cash as Myriad Narrows Its Focus to Oncology Labcorp (NYSE: LH) signed a definitive agreement to buy Myriad Genetics’ (NASDAQ: MYGN) Prenatal Health testing business, including the Prequel, Foresight, SneakPeek and FirstGene tests, for $210 million in cash plus inventory value at closing. Labcorp expects about $160 million of first-year revenue, slight accretion to adjusted EPS in year one, and average diagnostics-segment margins by the end of year two. The carve-out comes out of Myriad’s strategic review, after prenatal revenue fell about 16% in the first half of 2026. It follows closely on Labcorp’s $722 million BioReference deal. (Link)
  22. Risant Health has signed a definitive agreement to acquire INTEGRIS Health, Oklahoma’s largest nonprofit health system, pending regulatory approvals. INTEGRIS Health would become Risant’s third member system after Geisinger and Cone Health. Headquartered in Oklahoma City, INTEGRIS operates roughly 20 acute and specialty hospitals and the state’s largest physician network, employing about 13,000 people. It will keep its name, medical staff, brand and leadership. Risant, backed by Kaiser Permanente, is focused on value-based care; INTEGRIS leadership pointed to access to additional capital, technology including Epic, and clinical tools that the system could not scale on its own. (Link)
  23. Bolt Biotherapeutics, Inc. (NASD: BOLT) has completed the acquisition of Prana Therapies, Inc. in a stock-for-stock reverse merger concurrent with a $120 million private placement. The sign-and-close reverse merger exchanges Prana equity for Bolt common stock and Series D non-voting convertible preferred stock. A concurrent financing raises $120 million in upfront gross proceeds from the purchase of Series D preferred, with up to an additional $60 million available if accompanying warrants are exercised. Investors include Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Eventide Asset Management, Casdin Capital and Soleus Capital. The combination focuses on Prana’s INSPIRE platform and lead bispecific antibody PRA-216 (IL-4Rα/TSLP). Proceeds are expected to fund operations into 2028. Sheila Gujrathi, M.D., former Prana CEO, joins as chief strategy officer and board member. (Link)
  24. OpenAI Acquires a16z-, 8VC- and Insight-Backed Orchestra Bio to Bring Agentic Drug-Program Management into Its Rosalind Life Sciences Suite OpenAI acquired San Francisco-based Orchestra Bio on October 20. Orchestra’s AI agents help biopharma teams coordinate drug development programs — they monitor studies, track timelines and flag delays that can spread across a program. Orchestra came out of stealth in 2025 with about $20 million from investors including Andreessen Horowitz, 8VC and Insight Partners. Its team and technology will be folded into Rosalind, OpenAI’s life sciences offering, which already has pharma partners such as Moderna and Novo Nordisk. (Link)
  25. Hackensack Meridian Health Signs a Definitive Agreement to Acquire Hunterdon Health, Committing $230 Million to the Central New Jersey System Hackensack Meridian Health, New Jersey’s largest health system, signed a definitive agreement to acquire Hunterdon Health. Hunterdon is anchored by the 184-bed Hunterdon Medical Center teaching hospital and has more than 30 medical practices. HMH committed $230 million in investment, and the deal would bring it to 19 hospitals. No closing timeline was given. (Link)
  26. Beacon Biosignals Acquires Snap Diagnostics to Expand EEG-Enabled Home Sleep Testing Nationwide Beacon Biosignals, an AI-powered precision neurotechnology company, has acquired Snap Diagnostics, a national home sleep testing provider. Snap operates as a Medicare-registered Independent Diagnostic Testing Facility accredited by The Joint Commission and serves patients in all 50 states with end-to-end shipping, scoring and interpretation. The acquisition more than doubles Beacon’s patient reach and gives it a channel to bring its FDA-cleared EEG headband technology into primary care, telehealth and specialty settings starting in 2027. (Link)
  27. CentraCare and Stellis Health Announce Plans to Integrate, with Completion Targeted for January 1, 2027 CentraCare, the integrated nonprofit health system serving Central, Southwest and West Central Minnesota, and Stellis Health, a physician-owned medical group with more than 60 providers in Wright County, have announced plans for Stellis to become part of CentraCare. The combination builds on a longstanding partnership that already includes a shared Epic electronic medical record and collaboration at CentraCare – Monticello. Stellis shareholders have voted to proceed. (Link)
  28. Further Acquires Welbi to Combine Senior Living Sales AI with Resident Experience Management Further, the Charleston-based AI platform for senior living sales and marketing, has acquired Ottawa-based Welbi, a resident experience platform. Together they reach more than 8,000 senior living communities. Further’s suite (ProspectAI, SalesAI, ResidentAI, OpsAI) helps operators attract and convert prospects; Welbi helps communities personalize daily programming and track engagement. Welbi founder and CEO Elizabeth Audette-Bourdeau will continue to lead Welbi’s operations. (Link)
  29. Vimian Group Expands Its Veterinary Surgical Offering Through the Acquisition of Norfolk Medical Products Vimian Group AB (publ), the Stockholm-based animal health company, has signed an agreement to buy Norfolk Medical Products, a family-owned U.S. provider of implants and consumables for veterinary soft-tissue surgery. Norfolk, founded in 1981, does about $6.9 million in revenue and specializes in vascular access ports and related implantable solutions. The deal is Vimian’s first move into specialized soft-tissue surgery and is expected to have a marginal impact on 2026 earnings. (Link)

Venture Deals and Other

  1. Star Therapeutics has raised $200 million in private financing to advance its preclinical pipeline of novel biologics after prior exits of subsidiary assets. The round was co-led by OrbiMed and Janus Henderson Investors, with participation from RA Capital Management, Sofinnova Investments and others. Star, founded by Adam Rosenthal, has a history of discovering biologics and advancing them through subsidiaries that were later sold or taken public, including the sale of Vega Therapeutics to Incyte and the IPO of Electra Therapeutics. Rosenthal called the financing a reset, with the company focusing on early-stage programs rather than a hub-and-spoke model going forward. Proceeds will be used to move current preclinical assets into the clinic. (Link)
  2. OpenAI Startup Fund and Founders Fund Co-Lead a $45 Million Round for Coherence Neuro’s AI-Enabled Brain Tumor Implant The round was co-led by OrbiMed and Janus Henderson Investors, with participation from RA Capital Management, Sofinnova Investments and others. Star, founded by Adam Rosenthal, has a history of discovering biologics and advancing them through subsidiaries that were later sold or taken public, including the sale of Vega Therapeutics to Incyte and the IPO of Electra Therapeutics. Rosenthal called the financing a reset, with the company focusing on early-stage programs rather than a hub-and-spoke model going forward. Proceeds will be used to move current preclinical assets into the clinic. (Link)
  3. FirstMark Capital Leads a $40 Million Series A for Baba, with CVS Health Ventures Joining, to Build AI Care Teams for Medicare and Medicaid Members New York-based Baba, an applied AI company working on the Medicare and Medicaid experience, raised a $40 million Series A led by FirstMark Capital. CVS Health Ventures and Valtruis joined, and General Catalyst, Genius Ventures and Ground Up Ventures returned. The funding will expand Baba’s clinical care teams, advance its AI research and grow its health plan partnerships. (Link)
  4. Healthleap has raised $38 million in seed and Series A funding to expand its AI platform that flags at-risk hospital patients from electronic medical records. The total comprises an $8 million seed round co-led by Sequoia Capital and First Round Capital and a $30 million Series A led by Hummingbird Ventures. Founded in 2022 by siblings Jemima and Josiah Meyer, the South African-origin company analyzes clinical notes, labs, vitals and medication records to surface risk scores for conditions such as malnutrition and delirium. It is used in more than 50 hospitals including Penn Medicine, Cedars-Sinai, Houston Methodist and Emory Healthcare. (Link)
  5. Allumia Ventures Leads a $10 Million Series A for Home-Based Lung Disease Telehealth Provider Kivo Health Kivo Health, a telehealth provider of virtual pulmonary rehabilitation and care for COPD and other chronic lung diseases, raised a $10 million Series A led by Allumia Ventures, according to Axios Pro. Home-based respiratory care is an area health plans and risk-bearing providers have been looking at for value-based contracts. (Link)
  6. Zai Lab Limited (NASD: ZLAB; HKEX: 9688) has entered a securities purchase agreement for a $250 million PIPE financing of American Depositary Shares. Zai Lab agreed to sell 11,340,000 ADSs at $22.04 each, for expected gross proceeds of about $250 million before fees. The financing is led by TCGX and includes participation from abrdn World Healthcare Fund, ADAR1 Capital Management, Balyasny Asset Management, Cormorant Asset Management, Frazier Life Sciences, RA Capital Management, RTW Investments, Wellington Management and others. Net proceeds are intended primarily to support continued global development of zocilurtatug pelitecan (zoci), the company’s DLL3-targeting antibody-drug conjugate. Leerink Partners is the exclusive placement agent. (Link)

IPOs:

  1. Lycia Therapeutics Prices Upsized $317.5 Million Initial Public Offering at $18 per Share Lycia Therapeutics, Inc. (NASD: LYCA), a clinical-stage biotechnology company developing LYTAC degraders of disease-causing extracellular proteins, priced its upsized IPO of 17,640,000 shares at $18.00 per share, for expected gross proceeds of about $317.5 million. The company had originally marketed 14.7 million shares at $16–$18. Lead programs include LCA-0061 (an IgE degrader for food allergy) and LCA-0321 (an autoantibody degrader for Graves’ disease). Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are joint book-running managers. The platform is based on work by Nobel laureate Carolyn Bertozzi. (Link)
  2. Anthropic Files Public S-1 for Nasdaq IPO Under Ticker (NASD:ANT) Anthropic, the AI lab behind the Claude model family, has filed a public S-1 registration statement with the SEC for an initial public offering on Nasdaq under the ticker ANT. The Claude maker is targeting a valuation of $1.5–2 trillion, which would make it one of the largest IPOs on record and roughly double the $965 billion mark from its May funding round. First-half 2026 revenue was $16.3 billion, against about $4.6 billion for all of 2025. Third-quarter revenue reached $16.8 billion, up about 45% sequentially, and the company said it was profitable on an adjusted basis. The $80.7 billion first-half net loss is largely a non-cash charge tied to the rising valuation. (Link)
Spenser Lin No Comments

2nd Annual Healthcare Dealmaking At The Mountain – January 9th, 2027

Join us for the 2nd Annual Dealmaking at the Mountain which be taking place at South Lake Tahoe on Jan 9th 2027!


Dealmaking at the Mountain is an exclusive limited gathering of healthcare investors, executives, private equity finance stakeholders & innovation leaders. Purpose is to facilitate high-value deal discussions, networking, and thought leadership in healthcare private equity, set in an immersive environment combining business with outdoor winter elements (skiing, fireside networking, etc.).

Skiing not required; Snow not guaranteed.

Join us between CES and JP Morgan events!

Sponsored by Lawrence, Evans & Co., LLC & Dykema

Includes group skiing (ski pass and equipment not included) or events and an organized group discussion followed by sunset dinner.

Registration link: https://luma.com/jux7nt01

Spenser Lin No Comments

Lawrence, Evans & Co. Named Among Axial’s Top 10 Lower Middle Market Healthcare Sell-Side Advisors for 2026

Lawrence, Evans & Co., LLC has been recognized among the Top 10 sell-side advisors on Axial’s 2026 Top 50 Lower Middle Market Healthcare Investors & M&A Advisors list.

The annual list highlights Axial’s most active healthcare members over the prior 12 months. Rankings are based on deals brought to market, buyer interest in those processes, healthcare-focused investment mandates, and transactions that advanced through the deal funnel.

Lawrence, Evans & Co. is a national boutique healthcare financial advisory firm based in Columbus. We advise small and middle-market companies on mergers and acquisitions, capital raising, and special situations, with a focus on healthcare providers and services, logistics, and business services. Our work is concentrated with companies typically up to $250 million in revenue and/or $15 million in EBITDA.

We appreciate the recognition from Axial and the companies and capital partners who continue to work with us.

Read Axial’s full 2026 list here:
https://www.axial.net/forum/the-top-50-lower-middle-market-healthcare-investors-ma-advisors-2026/

Spenser Lin No Comments

Meet with our Team at ACG Columbus Aerospace & Defense Dealmaking & Investment Summit 2026 (Sept. 22, 2026, Columbus, OH)

Lawrence, Evans & Co., LLC is proud to sponsor the inaugural ACG Columbus Aerospace & Defense Dealmaking & Investment Summit 2026 in Columbus.

We advise small and middle-market companies on mergers and acquisitions, capital raising, and special situations, with a focus on healthcare providers and services, logistics, and business services. Our work is concentrated with companies typically up to $250M in revenue and/or $15M in EBITDA.

Aerospace & defense and healthcare have meaningful overlap — dual-use technology, medical logistics, cybersecurity, space health, and the capital that supports companies operating in both ecosystems.

In 2020 we published our bioastronautics paper about the potential overlap in industries.
Read the paper here: https://lnkd.in/guiYk2jk

We are currently working on a medical drone industry paper. If you have insight or input, we would value your feedback.
Read the working draft here: https://lnkd.in/gU8dgSYU

Managing Partner Neil Johnson will be on-site throughout the event. If you are attending, please connect with Neil in person, or visit us at https://lnkd.in/daXdAZvF.

Our other team members Spenser L., Kurtavya Joshi and Byron A. will also be present if Neil is not available.

Event details:
https://lnkd.in/gXhW3Pip

#ACG #ACGColumbus #MiddleMarket #Healthcare #AerospaceAndDefense #InvestmentBanking #MedicalDrones #Bioastronautics

Spenser Lin No Comments

Meet with our team at the ACG Great Lakes Capital Connection (Sept 9-10, 2026 | Indianopolis, IN)

Lawrence, Evans & Co. (LECO) is in Indianapolis on September 9–10, 2026 for ACG Great Lakes Capital Connection. Managing Partner Neil Johnson and Director Dave Opalek will be on-site throughout the conference and are available to meet with owners, operators, investors, and advisors.

LECO provides investment banking, financing, and consulting to small and middle-market healthcare providers and services companies, as well as logistics, technology, and business-services businesses. Typical clients are up to $250 million in revenue. The firm is known for practical solutions on complex M&A, growth capital, refinancings, and special situations.

What we have been working on

In August 2026, we hosted AI Secrets: How Healthcare Owners Can Maximize Efficiency & Valuations in partnership with Porter Wright Morris & Arthur LLP as the sponsor. The discussion focused on how owners are using AI to improve operations, protect margin, and build a more saleable business ahead of a raise or exit. Neil Johnson moderated a panel with Kathleen Van Schaik of Porter Wright, Tim Raderstorf of Steadywell, and BJ Yurkovich of Elevate CFO.

We also recently closed a $30 million refinance and growth-capital facility for a healthcare revenue cycle management platform. LECO led the process while the company completed acquisitions across multiple countries, structuring a non-dilutive refinance and acquisition line of credit around that expansion.

Earlier this year, Lawrence, Evans & Co. was presenting sponsor of the 6th Annual Healthcare Capital Markets & Innovation Summit (HCMIS) in Columbus. The 2026 program brought together nearly 500 healthcare operators, investors, lenders, and advisors around deal activity, private credit, AI, behavioral health, and longevity as an investment theme.

Why GLCC

Great Lakes Capital Connection is one of the region’s primary middle-market meetings. We will be there to compare notes on healthcare and services deal flow, listen for companies that need a refinance or acquisition facility, and stay in front of the sponsors and operators we work with across the Midwest.

If you will be in Indianapolis on September 9–10, reach out to Neil or Dave and set a time to meet.
If you aren’t able to be there, please feel free to reach out by e-mail:

Neil Johnson: njohnson@lawrenceevans.com
Dave Opalek: dopalek@lawrenceevans.com

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 4th, 2026

LECO_Weekly-Healthcare-News_5-4-2026Download
  1. UCB (ENX:UCB) to acquire clinical-stage biotech Candid Therapeutics for up to $2.2 billion to expand its immunology pipeline with novel T-cell engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics for $2 billion in upfront payments and up to $200 million in potential development milestones. The transaction, which hijacks Candid’s planned reverse merger with Rallybio, brings a pipeline of T-cell engagers (TCEs) led by cizutamig (BCMAxCD3), a Phase 1/2-ready bispecific antibody demonstrating deep B-cell and plasma cell depletion with manageable safety in autoimmune patients. This deal positions UCB to compete directly in the emerging TCE autoimmune field alongside Gilead, accelerating its strategy in high-unmet-need immune-mediated diseases through off-the-shelf, outpatient-compatible therapies. Candid’s additional assets, including a CD20xCD3 bispecific and preclinical trispecific TCEs, further strengthen UCB’s next-generation immunology platform. (Link)
  2. Chiesi Group to acquire KalVista Pharmaceuticals (NASD:KALV) for approximately $1.9 billion to strengthen its global rare disease portfolio Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) for $27.00 per share in cash, representing an equity value of approximately $1.9 billion. The transaction, Chiesi’s largest acquisition to date, adds EKTERLY® (sebetralstat), the first oral, on-demand plasma kallikrein inhibitor for hereditary angioedema (HAE) attacks in patients 12 years and older. Already approved in the U.S., EU, UK, Japan, and other markets with strong commercial uptake ($49 million in 2025 U.S. sales), sebetralstat will bolster Chiesi Global Rare Diseases’ immunology franchise and support the group’s 2030 revenue target of €6 billion. The deal is expected to close in Q3 2026, subject to customary closing conditions including a successful tender offer. (Link)
  3. Atrium Health and WakeMed propose $2 billion strategic combination to expand services and create 3,300 jobs in North Carolina Atrium Health (part of Advocate Health) and Raleigh-based WakeMed have announced a proposed merger that includes a $2 billion investment in Wake County, aimed at expanding access across North Carolina and creating approximately 3,300 new healthcare jobs over five years. The combination would unite North Carolina’s largest health system with the Triangle’s leading community-based provider, enhancing specialty services (cancer, neurosciences, pediatrics), building the state’s largest nonprofit mental health network (>360 inpatient beds), and establishing its largest virtual care platform. Key initiatives include redevelopment of WakeMed’s Raleigh campus, hospital expansions, new Healthplex facilities, and strengthened medical education partnerships with Wake Forest University School of Medicine. The non-binding proposal requires approval from the Wake County Board of Commissioners and is subject to regulatory review. (Link)
  4. CareDx (NASD: CDNA) to acquire Naveris for $160 million upfront plus up to $100 million in milestones to enter viral-mediated cancer MRD surveillance CareDx, Inc. has entered into a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company specializing in blood-based molecular residual disease (MRD) monitoring for HPV-driven cancers. The transaction includes $160 million in upfront cash consideration and up to an additional $100 million contingent on revenue milestones. Naveris’ flagship NavDx® test, based on proprietary Tumor Tissue Modified Viral (TTMV®) DNA technology, is Medicare-reimbursed and addresses a $4.5 billion total addressable market in head and neck, anal, and other viral-mediated cancers. The company generated approximately $34 million in unaudited 2025 revenue (with Q1 2026 revenue of ~$12 million at 65% gross margin) and has performed over 130,000 commercial tests to date. The acquisition extends CareDx’s precision medicine strategy from transplant diagnostics into specialty oncology while remaining neutral to 2026 Adjusted EBITDA guidance. The deal is expected to close in Q3 2026. (Link)
  5. CareMetx expands its patient access platform through the strategic acquisition of U.S.-based patient services and TheraCom free goods pharmacy operations from Cencora, Inc. (NYSE: COR) CareMetx has successfully completed the acquisition of Cencora’s (COR) U.S. Hub consulting services and its TheraCom pharmacy business to create a more robust technology-enabled services platform. This transaction integrates Cencora’s extensive staffing and pharmacy infrastructure with CareMetx’s AI-driven workflow automation. The deal positions CareMetx to serve over 155 pharmaceutical brands, focusing on reducing treatment barriers and improving patient access to specialty medications. Cencora will transition into a preferred partner role, ensuring a seamless transition for existing clients while leveraging CareMetx’s specialized digital solutions to enhance patient journeys across the healthcare ecosystem. (Link)
  6. Odyssey Therapeutics targets up to $810 million valuation in Nasdaq IPO for autoimmune and inflammatory disease pipeline Odyssey Therapeutics has filed to raise up to $238.3 million in its U.S. initial public offering by offering 13.2 million shares priced between $16 and $18 each, targeting a valuation of up to $809.9 million. The Boston-based biopharmaceutical company is developing precision therapies for autoimmune and inflammatory diseases, with lead candidate OD-001 in a mid-stage (Phase 2) trial for ulcerative colitis. Odyssey plans to list on Nasdaq under the ticker “ODTX,” with J.P. Morgan, TD Cowen, and Cantor serving as lead underwriters. The IPO comes amid a strong resurgence in biotech listings and would provide capital to advance its clinical pipeline in high-unmet-need immune-mediated indications. (Link)
  7. Infinite Epigenetics acquires Tally Health a longevity company co-founded by Dr. David Sinclair, seeded by L Catterton, to build a vertically integrated epigenetic testing platform Infinite Epigenetics has completed the acquisition of Tally Health, marking a major consolidation in the longevity and biological age testing market. The deal combines Tally Health’s consumer-facing brand and TallyAge™ test with Infinite Epigenetics’ scientific infrastructure and DNA methylation datasets. Tally Health will operate as a standalone consumer brand within the Infinite Epigenetics ecosystem, gaining access to advanced diagnostic tools from the TruDiagnostic arm. The acquisition is intended to accelerate the development of personalized interventions for aging and shift the healthcare focus toward proactive longevity. L Catterton, an initial investor in Tally, sees the exit as a milestone in the commercialization of biological age metrics. (Link)
  8. Global clinical research organization Parexel acquires Vitrana to integrate its AI-powered pharmacovigilance platform into Parexel’s comprehensive patient safety and clinical development services Parexel has bolstered its patient safety capabilities through the acquisition of Vitrana, a provider of AI-driven pharmacovigilance technology. The deal allows Parexel to offer an end-to-end safety model that automates data processing for regulatory submissions, reducing the administrative burden on clinical trials. Vitrana’s system-agnostic platform will be integrated into Parexel’s global infrastructure, enabling pharmaceutical clients to achieve greater accuracy in adverse event reporting. This strategic move aims to improve operational efficiency and global compliance while maintaining a focus on high-quality clinical outcomes. Vitrana will operate as a Parexel company, keeping its leadership team to drive continued technological innovation. (Link)
  9. Enterprise oncology platform Azra AI acquires Thynk Health to expand its AI-driven incidental findings and lung cancer screening platform across 500 hospitals Azra AI has acquired Thynk Health to create a unified platform for managing incidental medical findings and cancer screenings. The merger brings together two leaders in the oncology workflow space, serving a combined customer base that includes five of the top ten U.S. health systems. By integrating Thynk Health’s specific expertise in lung cancer screening, Azra AI enhances its ability to identify and track patients from the moment a potential issue is spotted in imaging. The combined entity aims to eliminate patient handoff failures and accelerate the diagnosis of life-threatening conditions. Thynk Health’s leadership will join Azra AI to oversee the expansion of the incidental findings platform. (Link)
  10. Quality data management leader Medisolv, Inc. acquires Health Elements AI to enhance its automated data abstraction and clinical registry reporting capabilities for healthcare organizations Medisolv has acquired Health Elements AI to modernize its clinical data extraction processes using advanced artificial intelligence. The acquisition targets the labor-intensive process of manual chart reviews, aiming to support the 4,000 abstracters using Medisolv’s platform across 1,800 hospitals. By integrating Health Elements’ AI-first software, Medisolv enhances its ability to capture structured data for critical reporting to organizations like the American Heart Association. This move follows Medisolv’s recent acquisition of Lilac Software, reinforcing its commitment to reinventing quality data usage. The combined technology will help healthcare providers transition more effectively to value-based care models by improving data accuracy and reducing staff burden. (Link)
  11. Pinnaql acquires Pharma Resource Group to expand scientific, formulation, and manufacturing advisory capabilities Pinnaql, Inc., a 3 Boomerang Capital portfolio company, has acquired Pharma Resource Group, Inc. (PRG), a provider of analytical sciences, formulation development, scientific writing, manufacturing, and change control advisory services to the pharmaceutical and life sciences industries. This marks Pinnaql’s third tuck-in acquisition in the past 10 months and significantly strengthens its end-to-end offering across the product lifecycle — from laboratory innovation and scale-up to validation, quality systems, regulatory compliance, and commercial readiness. Founded in 2007, PRG brings deep formulation and manufacturing expertise that complements Pinnaql’s existing strengths in engineering, validation, and quality consulting. The deal advances Pinnaql’s strategy to build a scaled, multi-disciplinary advisory platform serving biopharma, medical device, and CDMO clients. (Link)
  12. UConn Health signs letters of intent to acquire Bristol Hospital and Day Kimball Hospital as part of statewide expansion UConn Health has signed letters of intent to acquire Bristol Health (anchored by 154-bed Bristol Hospital) and Day Kimball Hospital (104-bed facility in Putnam), advancing its strategy to build a broader community hospital network across Connecticut. The non-binding agreements aim to close the Bristol transaction by January 2027 and the Day Kimball deal by fall 2026, subject to regulatory approval via the state’s Certificate of Need process. Both independent community hospitals have faced financial challenges, with negative operating margins in recent years, and the affiliations are expected to provide financial stability, expand access to academic medical center expertise, and strengthen UConn Health’s competitive position. The moves follow UConn’s recent acquisition of Waterbury Hospital and align with state-supported efforts to preserve essential healthcare services in the region. (Link)
  13. Nationwide Medical acquires Dynamic Healthcare Services (DHS) to expand home respiratory and durable medical equipment footprint Nationwide Medical, a leading provider of specialized respiratory care and home healthcare solutions, has acquired Dynamic Healthcare Services (DHS), a well-established provider of home respiratory supplies, durable medical equipment (DME), and oxygen therapy products serving Pennsylvania, New Jersey, and surrounding markets. The strategic acquisition strengthens Nationwide Medical’s regional presence and enhances its clinical programming for OSA, COPD, and other chronic respiratory conditions through DHS’s patient-centric model and strong local clinician relationships. This transaction expands access to comprehensive home-based care, including sleep therapy support, patient monitoring programs, and advanced equipment, while integrating DHS’s expertise with Nationwide Medical’s national infrastructure and remote monitoring capabilities. The deal aligns with Nationwide Medical’s growth strategy focused on improving therapy compliance and patient outcomes in the home medical equipment sector. (Link)
  14. The Ensign Group (NASD: ENSG)  acquires real estate and expands operations in Texas with new post-acute care campus The Ensign Group, Inc. has acquired the real estate and operations of a newly constructed 124-bed skilled nursing and rehabilitation facility in Texas, marking its continued expansion in the state. This transaction adds a modern, purpose-built campus to Ensign’s portfolio and brings the total number of operating facilities in Texas to 52. The acquisition aligns with Ensign’s disciplined “pay-for-performance” model and its strategy of entering high-quality, well-located assets in attractive markets. Financial terms were not disclosed. This move further strengthens Ensign’s presence in one of its key growth states and supports its long-term goal of portfolio diversification and operational scale in the post-acute care sector. (Link)
  15. Baystate Health and Trinity Health Of New England sign definitive agreement for integration of Mercy Medical Center Baystate Health has entered into a definitive agreement with Trinity Health Of New England to transition ownership of Mercy Medical Center (a 182-bed acute care hospital in Springfield, MA), its joint venture affiliates, and medical group entities to Baystate Health, subject to regulatory approvals. The transaction will allow Baystate to preserve Mercy’s nonprofit mission and Catholic legacy while providing financial stability and operational support to ensure long-term sustainability of high-quality local care in Western Massachusetts. Trinity Health Of New England will retain ownership of its Brightside for Families and Children services as well as continuing care operations, including Mercy LIFE, Beaven Kelly Home, and Saint Luke’s Home. The move addresses Mercy’s ongoing financial pressures from reimbursement challenges, outpatient shifts, and staffing shortages, strengthening regional access and positioning Baystate as a stronger safety-net provider for the Pioneer Valley. (Link)
  16. AI automation firm 1520ai acquires data insights firm Hospice Analytics to combine hospice-native artificial intelligence with established market utilization datasets. 1520ai has finalized the acquisition of Hospice Analytics, a firm with 20 years of experience in hospice data analysis. The merger unites 1520ai’s predictive modeling with Hospice Analytics’ deep market trends and utilization data to create a new platform focused on regulatory compliance and clinical quality. 1520ai, which has minority backing from simPAL Solutions, plans to use the acquisition to provide hospice providers with real-time answers to operational and financial questions. Hospice Analytics will maintain its branding and its partnership with the National Hospice Locator. (Link)
  17. Superior Health Holdings a Renovus Capital Partners portfolio company, acquires Chant Healthcare to expand its home health and hospice services into the Oklahoma market Superior Health Holdings has expanded into Oklahoma through the acquisition of Chant Healthcare, which operates as Compassion Homecare and Sans Bois Hospice. Backed by Renovus Capital Partners, Superior intends to leverage Chant’s strong presence in 11 Oklahoma counties and its large dual-eligible Medicaid patient base. The acquisition provides a strategic foothold for further expansion into the Oklahoma City and Tulsa markets. Chant Healthcare’s leadership will remain in place to manage local operations while utilizing Superior’s broader administrative and clinical infrastructure. This transaction marks Superior’s entry into its second state, following its established presence in Arkansas, and focuses on scaling rural healthcare delivery through specialized hospice services. (Link)
  18. The Medical University of South Carolina and Revival Healthcare Capital establish a five-year strategic innovation partnership to fund and scale next-generation medical technology solutions The Medical University of South Carolina (MUSC) has entered into a five-year partnership with private equity firm Revival Healthcare Capital to accelerate the commercialization of medical device innovations. Under the agreement, MUSC will provide clinical expertise and validation support for Revival’s portfolio companies, while Revival will provide the capital and operational leadership necessary to scale MUSC-originated technologies. This collaboration is designed to bridge the gap between academic research and commercial medical solutions. The partnership focuses on identifying unmet clinical needs and deploying high-impact medical devices into the healthcare market. Both organizations aim to create a repeatable model for innovation that improves patient outcomes through targeted investment and clinical rigor. (Link)

Venture Deals and Other

  1. DTC health platform Musely secures $360 million in non-dilutive capital from General Catalyst to accelerate customer acquisition for its dermatology and menopause care lines Musely has secured a $360 million capital commitment from General Catalyst through a non-dilutive financing structure. This arrangement allows Musely to fund aggressive marketing and customer acquisition efforts without giving up equity in the company. The funding will primarily support Musely’s core prescription skincare business and its recent expansion into the menopause care market. By utilizing non-dilutive capital, Musely maintains control over its operations while leveraging General Catalyst’s resources to scale its digital platform. The deal highlights a growing trend of high-growth, profitable direct-to-consumer health companies choosing creative financing over traditional venture rounds to fuel expansion. Musely plans to use the funds to reach millions of new patients globally. (Link)
  2. Bio-inspired BCI startup Axoft secures $55 million in Series A funding led by C.P. Group Innovation, with participation from Hillhouse Investment and Gaorong Ventures Axoft has raised $55 million in an oversubscribed Series A round to advance its implantable brain-computer interface (BCI) technology. The round, led by C.P. Group Innovation, included participation from Hillhouse, Gaorong, and the Stanford President’s Venture Fund, bringing Axoft’s total funding to over $60 million. Axoft is developing bio-inspired, soft implants that aim to provide long-term stability for neural communication without damaging brain tissue. The funding will support the expansion of global clinical trials, including the company’s first-in-human studies. This investment underscores the high demand for scalable BCI solutions that can treat neurological disorders. Axoft intends to use the capital to navigate regulatory approvals and scale its manufacturing capabilities. (Link)
  3. Truentity Health secures $35 million in oversubscribed Series A funding led by Evidenced VC, with participation from K-Street Capital, Cofounders Capital, and Tweener Fund. Truentity Health has closed a $35 million Series A round to scale its pharmacy-led clinical care model, which enables community pharmacies to provide chronic disease management services. The investment was led by Evidenced VC and saw participation from regional investors like Cofounders Capital and Tweener Fund. Truentity provides an AI platform that supports pharmacies in delivering reimbursable services such as remote patient monitoring and medication therapy management. The capital will be used to expand the company’s network into new state markets throughout 2026. By turning local pharmacies into clinical hubs, Truentity aims to improve healthcare access in rural areas and provide pharmacies with new, sustainable revenue streams. (Link)
  4. Prescription infrastructure startup Photon secures $16 million in Series A funding led by Healthier Capital, with participation from Notation, Flare Capital, and Evidenced Photon has closed a $16 million Series A funding round to modernize the digital prescription experience for patients and providers. The round was led by Healthier Capital and included participation from Flare Capital and Notation, bringing Photon’s total capital raised to over $25 million. Photon provides an API-driven infrastructure that allows patients to see real-time prescription pricing and stock availability at retail pharmacies. The new funds will support the expansion of Photon’s engineering team and the growth of its commercial partnerships with health systems and digital health brands. By simplifying the prescription routing process, Photon aims to reduce the estimated 20-30% of prescriptions that are currently abandoned by patients. (Link)
  5. AI pathology developer Techcyte bags $15 million in funding led by Van Tuyl Companies, with participation from strategic investors Zoetis Inc. (NYSE: ZTS) and Mayo Clinic. Techcyte has raised $15 million to scale its AI-powered digital pathology platform and drive the company toward profitability. The financing round was led by Van Tuyl Companies and saw continued support from Zoetis (ZTS) and Mayo Clinic. As part of the partnership, Techcyte will leverage Mayo Clinic’s massive dataset of 17 million pathology slides to further train its diagnostic algorithms. The Techcyte Fusion platform is designed to unify human, veterinary, and environmental pathology workflows into a single digital interface. The investment will be used to expand Techcyte’s global footprint and address the critical shortage of laboratory professionals by automating routine and complex diagnostic tasks. (Link)
  6. UnityAI launches its StaffOps platform for outpatient care following an $8.5 million Series A funding round led by Third Prime, with participation from Nashville Capital Network. UnityAI has introduced its AI-powered staffing and operations platform, StaffOps, following an $8.5 million Series A round led by Third Prime. The funding, which included participation from Whistler Capital Partners and Max Ventures, supports the company’s mission to optimize the outpatient healthcare workforce. StaffOps uses agentic AI to handle patient interactions and coordinate clinical tasks, currently managing over 300,000 interactions monthly. UnityAI has already partnered with large groups like Tennessee Oncology to improve clinical throughput and patient access. The new capital will be used to expand UnityAI’s go-to-market team and enhance its EHR integration capabilities, ensuring AI-driven tasks are safe, traceable, and highly efficient for medical staff. (Link)
  7. Specialty clinic automation startup TriFetch raises $1.9 million in pre-seed funding led by Nexus Venture Partners with participation from high-profile angel investors TriFetch has emerged from stealth with $1.9 million in pre-seed capital to develop AI automation tools specifically for independent medical practices. Nexus Venture Partners led the round, which also featured investment from notable angels affiliated with Google and Hippocratic AI. TriFetch’s platform acts as an automation layer that manages administrative tasks like patient scheduling, referral processing, and prior authorizations. Unlike traditional EHRs, TriFetch integrates with existing workflows to reduce the daily “paperwork” burden on clinicians. The funding will be used to build out the core product and expand its reach to more specialty clinics across the U.S., focusing on improving clinic profitability and reducing staff burnout. (Link)
  8. Depth Health raises $1 million in seed funding led by Green Harvest Capital Industries (GHC Industries) to scale its AI-driven hospital throughput optimization platform Depth Health has secured $1 million in seed financing to advance its Augmented Surveillance Intelligence (ASI) platform, which optimizes hospital patient flow and bed management. The funding round was led by Green Harvest Capital Industries, whose CEO, Ankit Patel, will join Depth Health’s Board of Directors. The capital will be used to enhance Depth Health’s explainable AI models, which provide real-time recommendations for patient placement and discharge. By joining the GHC Industries portfolio, Depth Health gains access to a broader ecosystem of clinical intelligence technologies. The investment aims to help hospitals reduce throughput bottlenecks and improve financial performance through data-backed operational efficiency. (Link)
  9. Virchu Sciences secures first institutional funding round to advance AI-powered oncology drug discovery platform Virchu Sciences has closed its first institutional investment round led by the Ohio Innovation Fund, with participation from JobsOhio Ventures and Rev1 Ventures. The Columbus, Ohio-based company operates at the intersection of AI, pharma, biotech, and academic research, developing multimodal AI solutions to accelerate drug discovery, advance treatment identification, and enable precision oncology testing. The new capital will support expansion of its data engineering and AI team, enhancement of its Data Discovery and Delivery Platform, and go-to-market efforts targeting academic institutions and commercial partners. The round underscores strong Ohio ecosystem support for AI-enabled life sciences innovation. (Link) (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Apr 13th, 2026

LECO_Weekly-Healthcare-News-4-13-2026Download

Healthcare Weekly News and Deals –April 13th, 2026

  1. FunctionHealth, a longevity-focused health tech startup for at-home-accessible lab testing, has acquired mobile healthcare platform Getlabs to bring comprehensive diagnostic services directly to consumers’ homes. Function, a health-tech company focused on proactive wellness, has acquired Getlabs, the leader in nationwide at-home lab draws. This acquisition allows Function to integrate a physical service layer into its digital platform, enabling members to have blood work and other diagnostics performed in the comfort of their homes. The investment is aimed at removing the friction traditionally associated with laboratory testing. By owning the logistical infrastructure of Getlabs, Function can ensure a standardized, high-quality experience for its users, furthering its mission to empower individuals with deep health insights through regular and accessible testing. (Link)
  2. Havencrest Capital Management has completed a majority recapitalization of Offor Health to accelerate the expansion of its clinical delivery model. Havencrest Capital Management, a healthcare-focused private equity firm, has finalized a majority recapitalization of Offor Health. This investment is designed to provide the necessary growth capital for Offor Health to scale its unique model of delivering high-quality clinical care, particularly in the dental and specialized surgical spaces. Havencrest’s involvement will focus on enhancing the company’s operational infrastructure and geographic footprint. The investor views Offor Health as a disruptive force in office-based clinical services, and the capital infusion will support the company’s mission to increase patient access and reduce costs for specialized procedures. (Link)
  3. ESO, backed by financial sponsors Vista Equity Partners and JSL Health Capital, has successfully acquired d2i to accelerate emergency intelligence and improve outcomes across fire, EMS, and health systems. ESO, a leading data and software vendor for emergency medical services (EMS), fire departments, and hospitals, has finalized its acquisition of d2i. The investment, supported by PE firms Vista Equity Partners and JSL Health Capital, aims to integrate d2i’s advanced data analytics and performance management tools into ESO’s ecosystem. This move is designed to provide healthcare professionals with deeper insights into clinical and operational performance. The investors are focused on scaling ESO’s ability to drive better patient outcomes through real-time data intelligence across the continuum of care. (Link)
  4. Council Capital and PMPK have partnered to acquire MedicalServiceQuotes.com to expand their healthcare procurement and analytics platform capabilities. Council Capital, a healthcare-focused private equity firm, alongside PMPK, has acquired MedicalServiceQuotes.com (MSQ). The investment is intended to bolster MSQ’s position as a leading platform for healthcare procurement, providing transparency and efficiency in medical service sourcing. By integrating Council Capital’s deep industry expertise and PMPK’s strategic resources, the company plans to scale its analytics and procurement tools. The investors aim to capitalize on the growing demand for cost-containment solutions in the healthcare sector, helping providers and payers optimize their spend through a more streamlined, data-driven digital marketplace. (Link)
  5. Qualifacts Systems, supported by financial sponsors Warburg Pincus, Martis Capital Management, and Clanton Capital, has completed the acquisition of MethodOne to enhance its behavioral health technology offerings. Qualifacts, a leading provider of electronic health records (EHR) for behavioral health, has expanded its portfolio by acquiring MethodOne. The deal is backed by a powerful consortium of investors including Warburg Pincus, Martis Capital, and Clanton Capital. MethodOne specializes in comprehensive clinic management software for opioid treatment programs. The investors are betting on the consolidation of specialized behavioral health software to create a unified platform that addresses the complex regulatory and clinical needs of addiction treatment providers. This acquisition strengthens Qualifacts’ market position as a premier technology partner in the behavioral health and human services sectors. (Link)
  6. Bioness Medical, via its financial sponsor Accelmed, has acquired the Portable Neuromodulation Stimulator (PoNS) system to bolster its neuro-rehabilitation portfolio. Bioness Medical, a subsidiary supported by the private equity firm Accelmed, has successfully acquired the PoNS system, a non-invasive medical device used in neurological rehabilitation. Accelmed’s strategic investment is aimed at integrating this innovative technology into Bioness’s existing suite of rehabilitation solutions. The acquisition allows Bioness to offer a more comprehensive range of therapies for patients suffering from neurological symptoms due to disease or trauma. Accelmed plans to utilize its expertise in the medical device sector to drive the commercial adoption and clinical validation of the PoNS system in global markets. (Link)
  7. DAS Health, backed by financial sponsor Coalesce Capital, has expanded its national footprint through the acquisition of Prime Care Technologies and Prime Cloud from Prime Holdings. DAS Health, a leader in healthcare IT and management services, has acquired Prime Care Technologies and Prime Cloud. This transaction was facilitated by Coalesce Capital, which provides the strategic funding and guidance for DAS Health’s aggressive expansion strategy. The acquisition integrates advanced cloud hosting and post-acute care technology solutions into DAS Health’s portfolio, enhancing its service offerings for long-term care facilities. Coalesce Capital is focused on building DAS Health into a dominant national provider of healthcare technology solutions, leveraging the synergies between these entities to offer comprehensive, integrated services to a wider range of medical providers. (Link)
  8. Sidekick Therapy Partners, supported by financial sponsors Green Hills Partners and Hillandale Advisors, has acquired Word of Mouth Clinical Associates to broaden its therapy service delivery. Sidekick Therapy Partners, a provider of pediatric therapy services, has acquired Word of Mouth Clinical Associates. The deal is backed by Green Hills Partners and Hillandale Advisors, who are focused on consolidating the fragmented pediatric therapy market. By acquiring Word of Mouth, Sidekick expands its reach and clinical expertise in speech, occupational, and physical therapy. The investors are committed to supporting Sidekick’s growth through operational improvements and strategic bolt-on acquisitions. This move strengthens Sidekick’s ability to provide high-quality, multidisciplinary care to children and families while creating a larger, more efficient regional platform. (Link)
  9. Livtech has successfully acquired Alora Healthcare Systems to integrate advanced home health software into its technology ecosystem. Livtech, a prominent player in healthcare technology, has announced the acquisition of Alora Healthcare Systems. This strategic acquisition focuses on Alora’s specialized software solutions for home health agencies. The investment is intended to create a more robust, end-to-end platform for home-based care providers, streamlining clinical documentation, scheduling, and billing. By integrating Alora’s technology, Livtech aims to provide a seamless user experience for healthcare professionals operating outside of traditional hospital settings. The acquisition reflects the increasing investment interest in home health technology as the industry shifts toward decentralized, patient-centric care models. (Link)
  10. Vertex Pharmaceuticals (NASD: VRTX) has entered into a definitive agreement to acquire Alpine Immune Sciences (NASD: ALPN) for approximately $4.9 billion to bolster its immunology pipeline. Vertex Pharmaceuticals is set to acquire Alpine Immune Sciences in an all-cash deal, significantly expanding its presence in the immunology and immunotherapy space. The acquisition centers on Alpine’s lead candidate, povetacicept, a potential best-in-class treatment for various autoimmune diseases. Vertex is utilizing its strong balance sheet to invest in high-potential late-stage clinical assets that complement its existing focus on serious diseases. This multi-billion dollar investment underscores Vertex’s strategy of diversifying beyond cystic fibrosis and acquiring innovative platforms that can address significant unmet medical needs in the protein engineering and immunology sectors. (Link)
  11. MKH Capital Partners has acquired Haven Health Management to provide growth capital for its 22 treatment locations across the United States. MKH Capital Partners, a family-backed private equity firm, has completed the acquisition of Haven Health Management. The investment provides significant growth capital to support Haven Health’s operations across its 22 addiction and mental health treatment facilities. MKH Capital Partners intends to use its resources to expand Haven Health’s geographic footprint and enhance its clinical services. The investor sees a substantial opportunity in the behavioral health sector, focusing on improving patient access to evidence-based treatment for substance use disorders. This deal highlights the continued interest of private equity in scaling established behavioral health platforms. (Link)
  12. Gilead Sciences, Inc. (NASD: GILD) has announced the acquisition of Tubulis to add a next-generation antibody-drug conjugate (ADC) platform to its oncology pipeline. Gilead Sciences is acquiring Tubulis to gain access to its proprietary ADC technologies, which are designed to create more stable and effective cancer therapies. This strategic investment is part of Gilead’s ongoing effort to diversify its portfolio into oncology and become a leader in targeted cancer treatments. The acquisition includes Tubulis’s diverse pipeline of ADC candidates and its innovative conjugation platforms. Gilead intends to leverage its extensive clinical development and commercialization expertise to accelerate the progress of Tubulis’s candidates, further strengthening its position in the rapidly evolving and highly competitive ADC market. (Link)
  13. BPOC has completed the sale of Midwest Products Engineering (MPE), marking the conclusion of a successful investment period for the private equity firm. BPOC, a healthcare-focused private equity firm, has finalized the sale of Midwest Products Engineering (MPE). During BPOC’s ownership, MPE expanded its capabilities as a leading design and manufacturing partner for medical device OEMs. The firm’s investment supported MPE’s growth through operational enhancements and strategic initiatives, positioning it as a critical supplier in the medical equipment market. This exit demonstrates BPOC’s ability to build value within the medical manufacturing sector. While the buyer was not disclosed, the sale highlights the strong demand for specialized manufacturing firms that serve the high-growth medical device industry. (Link)
  14. Response BPO has joined Carenet Health to exponentially grow its U.S. healthcare impact through expanded operations in South Africa. Carenet Health, a provider of 24/7 healthcare engagement and clinical solutions, has acquired Response BPO. This investment is strategically aimed at leveraging Response BPO’s operational strength in South Africa to enhance Carenet Health’s service delivery for U.S.-based healthcare organizations. The acquisition allows Carenet to offer more cost-effective and scalable engagement solutions, including clinical support and member services. By integrating Response BPO, Carenet Health strengthens its global delivery model, ensuring high-quality, continuous support for its clients while expanding its international footprint in the competitive business process outsourcing market within the healthcare sector. (Link)
  15. Telcor has acquired Sample Healthcare to lead an AI-driven transformation of revenue cycle operations for healthcare providers. Telcor, a leader in laboratory revenue cycle management (RCM) and point-of-care testing software, has acquired Sample Healthcare. This investment is focused on integrating Sample Healthcare’s AI capabilities into Telcor’s existing RCM platform. The goal is to automate complex billing processes, reduce denials, and improve the financial performance of laboratories and health systems. The investors believe that applying AI to revenue cycle operations will significantly increase efficiency and accuracy in healthcare billing. This acquisition reinforces Telcor’s position as an innovator in the RCM space, providing its clients with advanced tools to navigate the complexities of healthcare reimbursement. (Link)
  16. Blackstone and TPG Capital have completed the multi-billion dollar acquisition of medical technology leader Hologic, Inc. (NASD: HOLX). Private equity giants Blackstone and TPG have finalized their acquisition of Hologic, a prominent developer of diagnostic products and medical imaging systems. This strategic move aims to leverage Hologic’s market leadership in women’s health and surgical products to drive further innovation and global expansion. The investors plan to support the company’s R&D initiatives and enhance its operational capabilities through their extensive network and capital resources. This acquisition reflects the ongoing interest of top-tier private equity firms in high-performing medical technology assets with steady revenue streams and significant growth potential in the global diagnostics market. (Link)
  17. Seaport Therapeutics, a PureTech Health (LSE: PRTC) founded entity, has filed for a U.S. Initial Public Offering (IPO) to fund the development of its neuropsychiatric pipeline. Seaport Therapeutics, established by the biotherapeutics company PureTech Health, has officially filed for an IPO in the United States. The company is focused on advancing a pipeline of novel neuropsychiatric medicines using its proprietary Glyph platform, which is designed to enhance the oral bioavailability of drugs. The IPO proceeds are intended to fund clinical trials and further research into treatments for depression, anxiety, and other central nervous system disorders. This move marks a significant milestone for Seaport and its founding investors, as they seek to transition from a venture-backed entity to a public company to access broader capital markets for long-term growth. (Link)
  18. APM Human Services International Limited (ASX: APM) has acquired WorkCare to expand its occupational health and workforce wellness solutions across the global health and human services market WorkCare, a leading provider of occupational health and incident management services, has been acquired by APM Human Services International Limited (ASX: APM). This strategic acquisition allows APM to significantly bolster its “Health and Wellbeing” service vertical, integrating WorkCare’s clinical expertise in medical surveillance, onsite clinics, and telehealth. The investment is focused on scaling WorkCare’s delivery model across the United States and international markets, leveraging APM’s global infrastructure. The deal reflects the investor’s objective to address the increasing demand for integrated, data-driven employee health solutions that reduce workplace injuries and improve organizational productivity on a global scale. (Link)

Venture Deals and Other

  1. Chapter has raised $100 million in a new funding round led by Addition and NFX to simplify the Medicare enrollment process for seniors. Chapter, a technology-driven Medicare advisor, has secured $100 million in growth capital to expand its platform. The round was led by venture capital firms Addition and NFX, with participation from other existing investors. This significant investment will be used to enhance Chapter’s proprietary technology, which helps seniors navigate the complexities of Medicare to find the best-fitting coverage. The investors are backing Chapter’s unique model that searches every available plan, unlike traditional brokers. The capital will also support the hiring of additional advisors and the expansion of the company’s reach to more seniors across the United States. (Link)
  2. HeyDonto has closed a $20 million Seed round at a $200 million valuation to scale Conduit, its innovative dental interoperability exchange platform. HeyDonto, an AI-focused dental technology startup, has raised $20 million in Seed funding from a group of strategic venture investors. The round values the company at $200 million, reflecting strong investor confidence in its Conduit platform. Conduit is designed to solve the long-standing problem of data silos in dentistry by providing a seamless interoperability exchange for patient records and clinical data. The investment will be used to accelerate product development and expand the company’s sales and marketing efforts. The investors aim to position HeyDonto as the central infrastructure for the modern, data-driven dental practice, improving efficiency and patient care. (Link)
  3. SimpliFed has raised over $10 million in an oversubscribed Series A round to expand its maternal health ecosystem and improve access to breastfeeding support. SimpliFed, a maternal health company, has successfully closed a Series A funding round exceeding $10 million. The oversubscribed round included participation from several venture capital firms focused on health-tech and female-founded businesses. SimpliFed provides virtual breastfeeding support and baby feeding guidance, covered by insurance. The new capital will be used to scale the company’s operations, partner with more health plans, and expand its team of clinical experts. Investors are particularly interested in SimpliFed’s ability to provide high-quality, accessible maternal care that improves long-term health outcomes for both mothers and infants while reducing overall healthcare costs. (Link)
  4. Luminai has raised $38 million in a Series B funding round to scale its intelligence platform across health system operations and administrative workflows. Luminai, a company specializing in operational intelligence for healthcare, has secured $38 million in Series B funding. The round was led by prominent venture capital firms looking to capitalize on the automation of healthcare administration. Luminai’s platform uses AI to streamline complex workflows within health systems, reducing the administrative burden on staff and improving operational efficiency. The investment will be used to expand the company’s product features and accelerate its market penetration among large health systems. The investors see Luminai as a key player in solving the staffing shortages and burnout issues currently plaguing the healthcare industry through smart automation. (Link)
  5. Yuzu Health, a next-generation third-party administrator (TPA) providing unified infrastructure for health insurance plans, has raised $35 million in Series A funding. The round was led by General Catalyst and Chemistry, with participation from Anthropic’s Anthology Fund and others. The platform enables customizable plan designs through white-labeled claims processing, payments, and member administration. Proceeds will expand the engineering team and automate manual workflows to scale nationally. Investors see Yuzu Health as a key modernizer of outdated  infrastructure. (Link)
  6. Jimini Health, a clinician-supervised AI platform for behavioral health, has raised $17 million in seed funding led by M13 and Town Hall Ventures. Its Sage assistant integrates into care teams with full clinician oversight and visibility. The capital will support enterprise partnerships, expand clinical capabilities, and deepen EHR integrations. Investors view Jimini Health as a safe, scalable solution to responsibly deploy AI in mental health while addressing risks of unsupervised tools. (Link)
Spenser Lin No Comments

Recently Released Industry Report: Food as Medicine (FaM): How Food is Becoming a Trusted Part of Modern Healthcare

FoodAsMedicine.FaM_March2026Download

Food as Medicine (FaM) is rapidly gaining traction among investors and healthcare leaders — moving from a wellness trend into a reimbursable, outcomes-driven part of the healthcare system.

In our newly released industry paper “Food as Medicine (FaM): How Food Is Becoming a Trusted Part of Modern Healthcare”, we break down the current market dynamics, highlight proven cost savings, explore expanding reimbursement pathways, and show where the strongest investment opportunities lie today.

This report gives investors, analysts, and healthcare stakeholders the clear, practical insights needed to understand and successfully engage with this fast-emerging sector.

Highlights Include:   

  • How everyday food can dramatically improve health outcomes and lower costs
  • What “Food as Medicine” really means — and why it’s moving into mainstream healthcare
  • Medically Tailored Meals: Clinical results and real per-patient savings
  • Medical Nutrition Therapy and the expanding role of registered dietitians
  • The growing role of registered dietitians and scalable telenutrition counseling
  • High-margin Prescription Grocery models that leverage existing retail networks
  • The Food-as-Medicine Intervention Pyramid — from broad prevention to intensive care
  • Expanding policy tailwinds and new reimbursement pathways
  • Market maps, recent acquisitions, venture deals, and where the best opportunities sit today
Spenser Lin No Comments

Lawrence, Evans, and Co. (LECO) Presenting Sponsor for HCMIS 2026 (May 26-28th, 2026)

HCMIS-2026-LECO-Presenting-Sponsor-AnnouncementDownload

Lawrence, Evans & Co. LLC (LECO) is a leading national boutique healthcare financial advisory and investment banking firm headquartered in Columbus, OH.

Founded in 2003, LECO delivers specialized lead advisory services to lower middle-market private companies across the healthcare ecosystem. The firm’s experienced senior professionals provide a full suite of solutions, including:

● Sell-side and buy-side mergers & acquisitions advisory
● Capital raising (debt and equity)
● Valuation and Consulting
● Financial and Operational restructuring

LECO serves a wide range of healthcare sectors and related businesses, such as hospitals, senior housing, home health & hospice, behavioral and mental health, physician groups, longevity, revenue cycle management (RCM), digital health, HCIT, CCM, RPM, RTM, cyber & managed IT, pharma services, supply chain, life sciences, space health, real estate & more.

With a strong track record in driving strategic transactions, maximizing value, and fostering innovation, LECO is a trusted partner for healthcare providers, service companies, technology firms, and investors seeking impactful deals.

For more details on services, current engagements, or to connect, visit www.lawrenceevans.com. 

Contact Neil Johnson, Managing Partner, or David Opalek, Director

info@lawrenceevans.com or 614-448-1304

The 6th annual Healthcare Capital Markets & Innovation Summit HCMIS May 26-28th 2026 Columbus OH brings together 400+ dealmakers, investors, and innovators in healthcare.

More Information at www.healthcarecapitalmarkets.com

This conference is where leading healthcare industry executives gather and speak on the latest investment and partnership topics. In addition to hearing from top healthcare innovators, attendees will also have access to:

● Dealmaking & networking with industry leaders, executives, PE, VC, family offices, bankers, accountants, lawyers, and other professionals
● In-person one-on-one meetings with fellow event participants that can be locked in with a dedicated meeting scheduler
● Company presentations from executives seeking capital, partnerships, or to sell.
● ACG Columbus in collaboration with an event Day 2
● Healthcare Venture Studios (top leaders and investors in the space)
● Participants from over 32 US States and Globally
● Over $500 million of deal investment activities as a result of introductions
● Read Pitchbook’s Key Takeaways from HCMIS 2025
● *NEW*: PreConference Workshops Tues afternoon
● *NEW*: Emerging Company/Start Up Section – special pricing for qualified companies

Watch HCMIS 2026 Video

Watch HCMIS 2025 Highlights

HCMIS Overview Summary

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 2nd, 2026

LECO_Weekly-Healthcare-News_3-2-2026Download
  1. IQVIA (NYSE: IQV) Expands Early-Stage Drug Discovery Capabilities with Acquisition of Charles River Discovery Assets IQVIA Holdings Inc. (NYSE: IQV) announced an agreement to acquire select discovery services assets from Charles River Laboratories, strengthening its early-stage R&D capabilities. The assets include five sites offering in vitro drug discovery, AI-driven small molecule platforms, and advanced non-animal research methods backed by over 20 years of scientific data. These capabilities will enhance IQVIA’s integrated platform across drug discovery, from target identification to early safety assessment, covering key therapeutic areas like oncology, neurology, and immunology. The move positions IQVIA to support clients earlier in the drug development lifecycle. The transaction is expected to close in Q2 2026. (Link)
  2. GSK (NYSE: GSK) Agrees to Acquire 35Pharma for $950 Million to Bolster Cardiopulmonary Pipeline GSK announced an agreement to acquire 35Pharma Inc., a Canada-based clinical-stage biopharma company focused on novel protein-based therapeutics. The deal gives GSK full ownership of 35Pharma and its lead asset HS235, a potential best-in-class activin receptor signaling inhibitor targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). The acquisition strengthens GSK’s Respiratory, Immunology and Inflammation portfolio, addressing unmet needs in a high-burden disease with a growing market projected to reach $18 billion by 2032. GSK will pay $950 million in cash for 100% equity, subject to regulatory approvals, with closing expected thereafter. (Link)
  3. Exa Capital Expands Healthcare Software Portfolio with Acquisition of StaffReady, a Leader in Clinical Workforce Management SaaS Exa Capital, a long-term investor specializing in enterprise software, has acquired StaffReady, a SaaS platform for clinical workforce management in healthcare. Founded in 1995, StaffReady provides cloud-native tools for staff scheduling, compliance, and inspection readiness across hospital departments and life sciences organizations. The deal strengthens Exa Capital’s healthcare technology portfolio and marks its entry into clinical workforce optimization, a sector critical to operational efficiency and patient safety. StaffReady will continue to operate independently under Exa’s decentralized model, with its leadership team remaining in place to drive innovation and sustainable growth backed by Exa’s strategic support. (Link)
  4. Numantec Expands Infusion Therapy Portfolio with Acquisition of DualCap® Product Line from Merit Medical financed by Banco BPM and Muzinich & Co Numantec, a global infusion therapy device manufacturer, has acquired the DualCap® product line from Merit Medical Systems through its U.S. subsidiary, Health Line International Corp. The DualCap® is an established antimicrobial cap used in vascular access and infusion therapy, enhancing infection prevention and clinical efficiency. The acquisition strengthens Numantec’s vascular access portfolio and creates growth opportunities across Europe and the U.S., where DualCap® already has a strong customer base. Health Line, which has manufactured DualCap® since before 2017, will ensure continuity of supply. The transaction was financed by Banco BPM and Muzinich & Co. (Link)
  5. Healthcare Triangle (Nasd: HCTI) Announces $3.96 Million Registered Direct Offering Priced at-the-Market to Support Growth Initiatives Healthcare Triangle, Inc. (Nasdaq: HCTI), a digital transformation leader for healthcare and life sciences, announced it has entered into definitive agreements to sell 681,553 shares of common stock (or prefunded warrants) at $5.81 per share in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds are expected to total approximately $3.96 million before fees and expenses. The offering, conducted under the company’s effective Form S-3 shelf registration, is expected to close around February 27, 2026, subject to customary conditions. (Link)
  6. The HWP Group Acquires Global Market Access Solutions to Strengthen Market Access and Health Economics Expertise Backed by NMS Capital The HWP Group, a leading medical communications and strategic consulting firm for the life sciences sector, has acquired Global Market Access Solutions (GMAS), a global consultancy specializing in market access and health economics. The acquisition expands HWP’s capabilities in HEOR, pricing and payer insights, evidence synthesis, and lifecycle value strategy, enhancing support across the entire product lifecycle—from early development to sustained patient access. CEO Jani Hegarty said the deal reinforces HWP’s mission to bridge science and real-world access. Backed by NMS Capital, the move positions HWP as a fully integrated partner for pharmaceutical and biotechnology innovators. (Link)
  7. QC Capital Invests in My Pediatric Doctor to Expand Nationwide 24/7 Urgent Pediatric Telehealth Platform QC Capital Group, a Charlotte-based alternative investment firm, announced a strategic investment in My Pediatric Doctor, a nationwide 24/7 pediatric telehealth platform offering on-demand access to board-certified providers. Led by CEO Eric Doherty, the company aims to modernize pediatric care by reducing emergency room visits and improving accessibility for families across all 50 states, Guam, and Puerto Rico. The platform integrates with healthcare systems to relieve pressure on hospitals while maintaining high clinical standards. QC Capital CEO Chris Salerno called the partnership a key step in delivering trusted, affordable pediatric care nationwide. (Link)
  8. HCAP Partners Leads Follow-On Acquisition to Expand Integrated Diagnostic Services Platform with Core Analytics Lab & Radiology other partners include California Bank & Trust, along with co-investment from St. Cloud Capital and Southfield Mezzanine San Diego-based private equity and impact investor HCAP Partners has completed a follow-on acquisition for its Integrated Diagnostic Services (IDS) platform with the addition of Santa Fe Springs-based Core Analytics Lab & Radiology. The deal expands IDS’s footprint into Northern California and adds mobile laboratory diagnostics to its service offerings. Financing was provided by HCAP Partners, California Bank & Trust, along with co-investment from St. Cloud Capital and Southfield Mezzanine. Post-acquisition, IDS will serve over 440 facilities, offering bundled radiology and lab services to skilled nursing, long-term care, and home health providers across California. (Link)
  9. Gemspring Capital Expands Spinal Device Platform as Portfolio Company Zavation Medical Acquires ChoiceSpine Zavation Medical Products, a Gemspring Capital portfolio company and manufacturer of spinal implants and biologics, has acquired ChoiceSpine Holdings, a Knoxville-based spinal implant designer. The transaction broadens Zavation’s product portfolio and national reach, leveraging its vertically integrated manufacturing to accelerate innovation. ChoiceSpine will keep its brand and operations during integration. Concurrently, Zavation appointed Derek Kuyper as CEO of the combined entity. Gemspring Capital said the acquisition strengthens Zavation’s market position and supports its strategy to build a scaled, innovation-driven spinal platform. (Link)
  10. Fulcrum Equity Partners Leads $10M Growth Round in MedScout to Advance AI-Driven MedTech Sales Execution with participation from Live Oak Venture Partners and Stage 2 Capital Austin-based MedScout has raised $10 million in a growth funding round led by Fulcrum Equity Partners, with participation from Live Oak Venture Partners and Stage 2 Capital. The funding more than doubles MedScout’s valuation since its Series A in July 2024. The company also launched “Strategies,” a suite of AI agents designed to help MedTech commercial teams translate strategy into field-level execution. MedScout plans to use the capital to expand its AI capabilities amid surging enterprise demand. The company reported tripled enterprise revenue and rapid adoption growth as investors back its data-driven approach to commercial alignment in MedTech sales. (Link)
  11. Chapters Health Expands West Coast Footprint with Housecall Providers Deal, Strengthening Nonprofit Hospice Network and Growth Potential Chapters Health System, the nation’s largest nonprofit hospice network, has signed a definitive agreement to acquire Housecall Providers from CareOregon, pending approval by the Oregon Health Authority. The move expands its Pacific Northwest presence and adds to its 2025 West Division growth, which includes affiliates in California, Nevada, and Oregon. The integration aligns two nonprofit leaders in community-based chronic and homecare, reinforcing Chapters’ national scale, operational synergies, and value-based care capabilities—key drivers for investors tracking nonprofit healthcare consolidation and sustainable care delivery models. (Link)
  12. Dovida Enters U.S. Market with Acquisition of A Place At Home, Expanding Global Home Care Footprint to Seven Countries Global home care provider Dovida has entered the U.S. market through the acquisition of A Place At Home, a nationwide home care franchise network. The move marks Dovida’s seventh international market and first presence in North America, extending its person-centered care model across the United States. A Place At Home’s leadership will remain in place to ensure continuity for franchise owners and caregivers. The deal aligns with Dovida’s strategy to expand amid increasing demand for high-quality in-home care for older adults, reinforcing its mission to deliver personal, dignified, and relationship-based care on a global scale. (Link)
  13. Ally Bridge Group Backs Creation of Precision IO Group as Quantum Surgical Acquires NeuWave Medical to Advance Robotic Cancer Care Quantum Surgical has acquired NeuWave Medical, Inc., combining expertise in robotic and microwave ablation technologies under a new parent entity, Precision IO Group Inc., led by medtech veteran Kurt Azarbarzin. Supported by investment from Ally Bridge Group, the group aims to expand access to minimally invasive, AI-driven, and remote cancer treatments worldwide. Both companies will continue operating independently, ensuring ongoing product availability. The Epione robotic platform and NeuWave’s microwave system will together drive broader adoption of next-generation interventional oncology procedures across global healthcare markets. (Link)
  14. HIAAH Expands Mental Health Footprint with Strategic Acquisition of Broward Center for Counseling to Strengthen Market Presence in Broward County HIAAH, a U.S.-based integrated health care and mental health services provider, has acquired the Broward Center for Counseling as part of its expansion strategy in Broward County. The move reinforces HIAAH’s mission to broaden access to high-quality, compassionate mental health care while improving operational efficiency and client experience. The newly branded Broward Center for Counseling by HIAAH will continue providing individualized therapy for anxiety, depression, trauma, and relationship issues, now supported by enhanced infrastructure and a holistic, multidisciplinary care model. The acquisition aligns with HIAAH’s growth objectives and positions it for stronger long-term value creation in the behavioral health sector. (Link)
  15. UConn Health Finalizes Waterbury Hospital Acquisition from Prospect Medical Holdings UConn Health is set to complete its acquisition of Waterbury Hospital from bankrupt for-profit Prospect Medical Holdings at midnight on Saturday, marking a major expansion of its health network. The facility will operate under a new entity, UConn Health Community Network, beginning Sunday at 12:01 a.m. Immediate changes include new signage, updated processes, and a ribbon-cutting ceremony on March 4. UConn Health plans to assess Waterbury’s healthcare needs, modernize information and safety systems, and introduce new specialists and services from its flagship John Dempsey Hospital in Farmington to strengthen local medical care and patient outcomes. (Link)
  16. Bradford Health Expands into Midwest with Acquisition of Parkdale Center, Strengthening National Footprint in Specialized Professional Addiction Care Bradford Health Services, a nationally recognized addiction treatment provider, has acquired Parkdale Center, a leading Indiana-based facility specializing in confidential addiction recovery programs for healthcare providers, attorneys, executives, and other licensed professionals. The deal extends Bradford’s geographic reach into the Midwest and enhances its portfolio of evidence-based treatment offerings. Parkdale’s expertise in professional recovery, career reentry, and collaboration with licensing boards complements Bradford’s mission of clinical excellence and sustainable outcomes. Both organizations will maintain their brands while integrating operations to deliver expanded, high-quality care for professionals nationwide. Terms of the transaction were not disclosed. (Link)
  17. Zemantics Ventures Strengthens Healthcare Portfolio with Acquisition of Consilium360 and MedWell360 Zemantics Ventures, a strategic investment and operating platform, has acquired Consilium360 and MedWell360 to expand its presence in healthcare services and workforce solutions. The move enhances Zemantics’ capabilities in enterprise HR optimization, patient access, and technology-enabled operational performance. Consilium360 provides data-driven workforce and HR strategy solutions for healthcare systems, while MedWell360 specializes in scheduling and access center services. The acquisitions support Zemantics’ strategy of scaling founder-led, service-driven businesses through strategic capital, shared infrastructure, and technology. John Brown, Founder and Healthcare HR Executive, will continue in a leadership role to ensure continuity and growth. (Link)
  18. Epiphany Dermatology Expands Kansas Presence Through Partnership with Resolute Dermatology Epiphany Dermatology, a leading national dermatology network, has expanded its presence in Kansas by partnering with Resolute Dermatology, LLC, founded in 2020 by Dr. Daniel Christiansen. Based in Leawood and Shawnee, KS, Resolute Dermatology is recognized for high-quality patient care in the greater Kansas City area. The partnership brings Dr. Christiansen and his team—Drs. Julie Green, Elizabeth Spenceri, and PAs Judy Ky and Kylie Witham—into Epiphany’s growing network. Through this collaboration, Resolute gains operational and clinical support while sharing expertise across Epiphany’s 123 locations in 18 states, strengthening access to exceptional dermatologic care in the region. (Link)

Venture and Other News:

  1. NewSpring Healthcare Leads $140 Million Investment in Honest Health to Accelerate Value-Based Care Expansion included participation from K2 HealthVentures and existing investors Rubicon Founders, Oak HC/FT, WCAS, and Durable Capital Partners Honest Health, a physician-led value-based care enablement firm, raised $140 million in a funding round led by NewSpring Healthcare, the healthcare-focused arm of NewSpring Capital. The round included participation from K2 HealthVentures and existing investors Rubicon Founders, Oak HC/FT, WCAS, and Durable Capital Partners. Proceeds will support national expansion and partnerships with health systems and payers. NewSpring will leverage its sector expertise to guide Honest Health’s growth in risk-based care models. (Link)
  2. NantWorks Leads $240 Million Investment in SHINE Technologies; Dr. Patrick Soon-Shiong Joins Board to Advance Fusion and Cancer Therapies SHINE Technologies, a leader in fusion-based technology, has raised $240 million in new equity funding led by NantWorks, founded by Dr. Patrick Soon-Shiong, who also joins SHINE’s Board of Directors. Other investors include Fidelity, Sumitomo, Pelican Energy, Deerfield, and Oaktree. The funding supports SHINE’s commercial fusion initiatives in neutron testing, medical isotope production, and nuclear waste recycling, while accelerating Lu-177 radioisotope supply for precision cancer therapies. The strategic partnership gives NantWorks priority access to Lu-177, aligning SHINE’s fusion expertise with Soon-Shiong’s mission to transform oncology. With this round, SHINE’s total funding surpasses $1 billion. (Link)
  3. BrainCheck Secures Additional $13 Million Series A to Scale AI-Enabled Cognitive Care Platform and Embedded Assessment Workflows Across Value-Based Health Systems BrainCheck, a digital platform for cognitive assessment and care, has raised an additional $13 million in Series A financing led by Next Coast Ventures, with S3 Ventures and UPMC Enterprises participating. The capital will expand its enterprise cognitive care infrastructure, including deeper EHR integration, longitudinal monitoring, AI-assisted population health analytics, and deployment across primary care and specialty settings. BrainCheck is partnering with collaborative care organizations to operationalize scalable cognitive care pathways in time-constrained, value-based environments. Used by 500+ providers, its FDA Class II BrainCheck Assess™ has powered over 640,000 assessments and 14,000 care plans to date. (Link)
  4. YOU(th) Health Tech Raises $4.5M to Expand Smartphone-Based Preventive Health Screening Globally round led by Callisto Health, with support from caesar., adesso Ventures, Antler, Moonstone, and 1024 Ventures. Digital health startup YOU(th) has raised $4.5 million in a funding round led by Callisto Health, with support from caesar., adesso Ventures, Antler, Moonstone, and 1024 Ventures. Angel investors include Jean-Charles Samuelian (Alan, Mistral AI) and Patrick Andrae (HomeToGo). The company aims to democratize preventive healthcare by turning everyday smartphone data—such as facial videos, voice, typing patterns, and step counts—into quick health assessments detecting over 50 biomarkers across 10 organ systems. The funds will support product development and expansion of engineering, data science, and medical research teams to make preventive care accessible worldwide. (Link)
  5. General Catalyst Leads $6.5M Seed in Baba to Build Continuous AI‑Enabled Patient Advocacy for Aging Americans General Catalyst has led a more than $6.5 million seed round in Baba, a patient advocacy startup founded by Connor Sweeney to help seniors and families navigate complex healthcare logistics. Inspired by his grandparents’ experience after his grandmother’s stroke, Sweeney built Baba to pair older adults with dedicated human advocates, augmented by AI tools for daily check-ins, medication management, and insurance and benefits navigation. With advocacy reimbursed by Medicare for over 70 million beneficiaries, Baba aims to scale continuous, preventive support through partnerships with home health, nursing homes, and post-acute care providers. (Link)
  6. Coral Care Raises $13M Series A Led by Haymaker Ventures, Joined by FCA Ventures, Peterson Ventures, Alleycorp, Reach Capital, Jefferson River Capital, Greymatter Capital, Mother Ventures, and Charge Ventures to Expand In-Home Pediatric Therapy Nationwide Coral Care, a platform providing in-home pediatric speech, occupational, and physical therapy, has raised a $13 million Series A round led by Haymaker Ventures, with participation from FCA Ventures, Peterson Ventures, Alleycorp, Reach Capital, Jefferson River Capital, Greymatter Capital, Mother Ventures, and Charge Ventures. The funding will fuel national expansion in Dallas, Houston, Chicago, Philadelphia, and Pittsburgh, bringing operations to five states. Founded in 2023 by Jen Wirt, Coral Care supports over 400 licensed clinicians through its technology platform that streamlines administrative tasks and enables accessible, insurance-covered, in-home therapy for children across the U.S. (Link)
  7. AI Healthtech Startup Lexi Raises $1.4M Pre-Seed Round Led by Informed Ventures, Backed by HBS Alumni Angels, Stanford Angels, Alumni Ventures, and Van Wickle Ventures Lexi, an AI-native communication platform for healthcare, has raised an oversubscribed $1.4 million pre-seed round led by Informed Ventures, with participation from HBS Alumni Angels, Stanford Angels, Alumni Ventures, and Van Wickle Ventures. Founded by Linh Pham and Siddharth UR, Lexi tackles language barriers affecting 30 million U.S. patients by providing secure, instant AI interpretation within clinical workflows. A successful pilot with Lowell Community Health Center delivered over 60,000 minutes of interpretation, reduced costs by 60%, and improved privacy and efficiency. Lexi plans to expand deployments across health centers while broadening language coverage and patient partnerships. (Link)